阿德福韦对比恩替卡韦治疗慢性乙型病毒性肝炎的临床研究

发布时间：2018-07-25 17:12

【摘要】：目的评价阿德福韦对比恩替卡韦治疗慢性乙型病毒性肝炎(乙肝)的临床疗效及安全性。方法 86例慢性乙肝患者随机分为阿德福韦组(41例)和恩替卡韦组(45例),分别口服阿德福韦0.5 mg·d-1和恩替卡韦10 mg·d-1,疗程均为12个月。比较2组患者治疗前后乙肝病毒(HBV)DNA载量、病毒转阴率及药品不良反应。结果治疗12个月后,阿德福韦组与恩替卡韦组患者HBV DNA病毒载量[(4.21±0.71)vs(4.01±0.68)log10copies·m L-1]较治疗前均明显降低,差异有统计学意义(P0.05)。2组HBV DNA转阴率及谷丙转氨酶(ALT)正常率差异无统计学意义(P0.05)。2组患者不良反应发生率差异无统计学意义(P0.05)。结论阿德福韦与恩替卡韦治疗慢性乙肝均有较好的临床疗效,且不良反应轻微。
[Abstract]:Objective to evaluate the efficacy and safety of adefovir contrast entecavir in the treatment of chronic viral hepatitis B. Methods 86 patients with chronic hepatitis B were randomly divided into adefovir group (n = 41) and entecavir group (n = 45). Hepatitis B virus (HBV) DNA load, virus negative rate and adverse drug reaction were compared before and after treatment. Results after 12 months of treatment, the viral load of HBV DNA in adefovir group and entecavir group [(4.21 卤0.71) vs (卤0.68) log10copies mL -1] was significantly lower than that before treatment. There was no significant difference in the negative rate of HBV DNA and the normal rate of alanine aminotransferase (ALT) in group 2 (P0.05). There was no significant difference in the incidence of adverse reactions in group 2 (P0.05). Conclusion both adefovir and entecavir have good clinical efficacy in the treatment of chronic hepatitis B, and the adverse reactions are mild.
【作者单位】：遂昌县人民医院药剂科;丽水市人民医院感染科;
【基金】：浙江丽水市科技基金资助项目(2012JYBZ15)
【分类号】：R512.62

【参考文献】